Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2351-2358

  Hillner, Bruce E ^a   Kirkwood, John M ^a   Atkins, Michael B ^a   Johnson, Eric R ^a   Smith, Thomas J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; MODEL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030912852     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2351     Document Type: Article

References (25)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, et al: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7-17, 1996
2. Sonnenberg FA, Beck JR: Markov models in medical decision making: A practical guide. Med Decis Making 13:322-338, 1993
3. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 324:160-168, 1991
4. Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055-2061, 1992
5. Hillner BE, Desch CE, Carlson RW, et al: Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. J Clin Oncol 14:100-104, 1996
6. Hillner BE, McLeod DG, Crawford ED, et al: Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology 45:633-640, 1995
7. Crowley NJ, Seigler HF: Relationship between disease-free interval and survival in patients with recurrent melanoma. Arch Surg 127:1303-1308, 1992
8. Slingluff CL Jr, Dodge RK, Stanley WE, et al: The annual risk of melanoma progression. Implications for the concept of cure. Cancer 70:1917-1927, 1992
9. Morton DL, Essner R, Kirkwood JM, et al: Malignant melanoma, in Holland JF (ed): Cancer Medicine (ed 4) Philadelphia, PA, Lea & Febiger, 1996, pp 2467-2499
10. Crowley NJ, Seigler HF: Late recurrence of malignant melanoma. Analysis of 168 patients [see comments]. Ann Surg 212:173-177, 1990
11. Balch CM, Soong SJ, Shaw HM, et al: An analysis of prognostic factors in 8500 patients with cutaneous melanoma, in Balch CM (ed) Cutaneous Melanoma (ed 2). Philadelphia, PA, Lippincott, 1992, pp 165-187
12. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
13. Kochanek KD, Hudson BL: Advance report of final mortality statistics, 1992, in Monthly Vital Statistics Report (vol 43). Hyattsville, MD, National Center for Health Statistics, 1995
14. Goodwin PJ, Feld R, Evans WK, et al: Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 6:1537-1547, 1988
15. Weeks J, O'Leary J, Fairclough D, et al: The "Q-tility index": A new tool for assessing health related quality of life and utilities in clinical trials and clinical practice. Proc Am Soc Clin Oncol 13:1498, 1994 (abstr)
16. Task force on principles for economic analysis of health care technology: Economic analysis of health care technology: A report on principles. Ann Intern Med 122:61-70, 1995
17. Gold MR, Siegel JE, Russel LE, et al (eds): Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University, 1996
18. Cole BF, Gelber RD, Kirkwood JM, et al: Quality-of-life adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk cutaneous melanoma: An Eastern Cooperative Oncology Group study. J Clin Oncol 14:2666-2673, 1996
19. Smith TJ, Hillner BE, Desch CE: Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis. J Natl Cancer Inst 85:1460-1474, 1993
20. Edelson JT, Weinstein MC, Williams L, et al: Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 263:407-413, 1990
21. Laupacis A, Feeny D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146:473-481, 1992
22. O'Brien BJ, Drummond MF, Labelle RJ, et al: In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 32:150-163, 1994
23. Brown ML, Nayfield SG, Shibley LM: Adjuvant therapy for stage III colon cancer: Economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 86:424-430, 1994
24. Elit LM, Gafni A, Levine MN: Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: An Ontario perspective. J Clin Oncol 15:632-639, 1997
25. Cook RJ, Sackett DL: The number needed to treat: A clinically useful measure of treatment effect. BMJ 310:452-454, 1995